食管鳞癌XRCC1和ERCC1表达与同期放化疗疗效及预后的相关性分析  

Analysis of correlation between protein expression of XRCC1 and ERCC1 with efficacy of concurrent radiochemotherapy and the prognosis of patients with esophageal aquamous cell carcinoma

作　　者：张耀文[1] 周福有[1] 徐瑞平[1] 李铭[1] 郑志勇[1] 任润川 孙荣刚[1] 郑安平[1] 

机构地区：[1]安阳市肿瘤医院,河南安阳455000

出　　处：《河南医学研究》2016年第8期1357-1361,共5页Henan Medical Research

基　　金：安阳市科技攻关项目(2014)

摘　　要：目的探讨食管鳞状细胞癌（ESCC）组织中X线修复交叉互补基因1（XRCCl）和切除修复交叉互补基因1（ERCCl）的蛋白表达与同步放化疗疗效及预后的相关性。方法采用免疫组织化学S—P法检测治疗前98例ESCC组织标本中XRCCl和ERCCl蛋白表达。Kaplan—Meier法生存分析并Logrank法检验表达的生存差异，Cox模型多因素预后分析。结果XRCCl、ERCCl阳性主要表达于细胞核，两者表达无明显相关性（r=-0，024，P=0．811）。XRCCl蛋白在ESCC组织和正常食管黏膜组织的阳性表达率分别为57．1％（56／98）、13．3％（4／30）（χ2=17．702，P=0．000）。ER-CCI蛋白在ESCC组织和正常食管黏膜组织的阳性表达率分别为36．7％（36／98）、10％（3／30）（χ2=7．749，P=0．006）。XRCCl表达水平与临床病理特征均无关（P〉0．05）。ERCCl蛋白在有淋巴结转移组的阳性表达率为44．9％（31／69），高于无淋巴结转移患者的17．2％（5／29），两者差异有统计学意义（χ2=8．183，P=0．004）。XRCCl表达阳性组、阴性组患者的近期疗效和总生存期相似（r=0．894，P=0．344；χ2=0．266，P=0．606）。ERCCl阴性表达组的有效率为90．3％（56／62），较阳性表达组的80．5％（29／36）略有升高（χ2=1．888，P=0．169）。ERCCl表达阳性组、阴性组患者的中位生存期分别为25个月（95％CI：18．559—31．441个月）、39个月（95％CI：29．313～48．687个月），阴性组明显高于阳性组，差异有统计学意义（χ2=10．174，P=0．001）。多因素分析结果显示ERCCl表达与生存期密切相关，是独立的预后因素（P=0．010，95％CI：1．180～3．450）。结论ERCCl表达与放化疗疗效相关，阳性表达的患者与不良预后有关。Objective To analyze the correlation between protein expression of X - ray repair cross complementing group 1 （ XRCC1 ） and excision repair cross complementing 1 （ ERCC1 ） with efficacy of concurrent radiochemotherapy（CRT） and the prognosis of patients with esophageal aquamous cell carcinoma（ESCC）. Methods Immunohistochemical SP method was used to measure the protein expression of XRCC1 and ERCC in 98 ESCC tissue samples before CRT. The Kaplan - Meier method was used for survival analysis, and the log rank test was used for analyzing the survival difference between negative and positive sam- pies. The Cox model was used for multivariate prognostic analysis. Results XRCC1 and ERCC1 protein were mainly expressed in the nucleus in ESCC. There was no correlation between them （r = -0. 024,P = 0. 811 ）. The positive expression rate of XRCC1 protein in ESCC tissues and normal esophageal tissues were 57. 1% （56/98） and 13.3% （4/30） respectively （χ2 = 17.702, P = 0. 000）. The positive expression rate of ERCC1 protein in ESCC tissues and normal esophageal tissues were 36.7% （36/98） and 10% （3/30） respectively（χ2 = 7. 749, P = O. 006）. The level of ERCC1 was not correlated with clinical pathologic characteristics （P 〉 O. 05 ）. The positive expression rate of ERCC1 protein in negative lymphnode group was 44. 9% （31/69）, higher than 17. 2% （5/29） in positive lymphnode group, and the difference was statistically significant （χ2 = 8. 183, P = 0. 004）. The patients with positive XRCC1 expression and negative XRCC1 expression had similar short -term responses （χ2 = 0. 894, P =0. 344） as well as similar survival rates（χ2=0. 266, P =0. 606）. The RR of ERCC1 negative expression group was 90. 3% （56/62）, and the RR of ERCC1 positive expression group was 80. 5% （29/36）, but there was no statistically significant difference （χ2 = 1. 888, P =0. 169）. The median overall survival periods of ERCC1 negative expression group was 39 months （95% CI： 29.

关 键 词：食管肿瘤/放射疗法 X射线修复交叉互补基因1 切除修复交叉互补基因1 预后 

分 类 号：R735.1[医药卫生—肿瘤]